Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages.

Cyclodextrins and liposomes have been used in recent years as drug delivery vehicles, improving the bioavailability and therapeutic efficacy of many poorly water-soluble drugs. In this study, we used two approaches to enhance the availability of the poorly water-soluble antibiotic, clarithromycin, by inclusion complex formation and by liposome-encapsulation. We examined the efficacies of these formulations against Mycobacterium avium complex (MAC) in human peripheral blood monocyte-derived macrophages. The water solubility of clarithromycin was enhanced by about 700-fold by complexation with cyclodextrin. The use of a rapid radiometric (BACTEC) method for the detection of MAC growth and susceptibility showed identical MICs against MAC for both the free and complexed drug. The anti-MAC efficacy of the cyclodextrin complex of clarithromycin in macrophages was slightly lower than the free drug, probably due to the high stability of the inclusion complex. At higher drug concentrations, Liposome-encapsulated clarithromycin was slightly more effective against intracellular MAC growth than the free drug.

[1]  P. Gangadharam,et al.  Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice. , 1991, The Journal of antimicrobial chemotherapy.

[2]  E. Wolinsky.  Mycobacterium avium strains resistant to clarithromycin and azithromycin , 1994, Antimicrobial Agents and Chemotherapy.

[3]  S. Naik,et al.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex , 1989, Antimicrobial Agents and Chemotherapy.

[4]  C. Horsburgh,et al.  The pathophysiology of disseminated Mycobacterium avium complex disease in AIDS. , 1999, The Journal of infectious diseases.

[5]  P. Gangadharam,et al.  Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes , 1995, Antimicrobial agents and chemotherapy.

[6]  P. S. Skinner,et al.  Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model , 1995, Antimicrobial agents and chemotherapy.

[7]  S. Alvarez-Elcoro,et al.  The macrolides: erythromycin, clarithromycin, and azithromycin. , 1999, Mayo Clinic proceedings.

[8]  D. Friend,et al.  Treatment of Mycobacterium avium-intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment. , 1991, The Journal of infectious diseases.

[9]  P. Fernandes,et al.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium , 1989, Antimicrobial Agents and Chemotherapy.

[10]  V. Stella,et al.  Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. , 1996, Journal of pharmaceutical sciences.

[11]  Y. Oh,et al.  Intracellular fate of Mycobacterium avium: use of dual-label spectrofluorometry to investigate the influence of bacterial viability and opsonization on phagosomal pH and phagosome-lysosome interaction , 1996, Infection and immunity.

[12]  W. Saenger,et al.  Inclusion Compounds. XIX.1a The Formation of Inclusion Compounds of α-Cyclodextrin in Aqueous Solutions. Thermodynamics and Kinetics , 1967 .

[13]  Y. Oh,et al.  Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection , 1995, Antimicrobial agents and chemotherapy.

[14]  T. Loftsson.  Pharmaceutical applications of β-cyclodextrin , 1999 .

[15]  A. Hersey,et al.  Mechanism of inclusion-compound formation for binding of organic dyes, ions and surfactants to α-cyclodextrin studied by kinetic methods based on competition experiments , 1986 .

[16]  Nalin Rastogi,et al.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex , 1991, Antimicrobial Agents and Chemotherapy.

[17]  R. Dahl,et al.  Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic , 1991, Infection and immunity.

[18]  G. Plosker,et al.  Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome. , 1993, Drugs.

[19]  C. Kemper,et al.  Mycobacterium Avium Complex , 2017 .

[20]  E. Vittinghoff,et al.  The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients--a prospective study. , 1994, The Journal of infectious diseases.

[21]  P. Schlesinger,et al.  Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. , 1998, Journal of immunology.

[22]  D. Friend,et al.  Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages , 1992, Antimicrobial Agents and Chemotherapy.

[23]  C. Truffot-Pernot,et al.  Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages , 1990, Antimicrobial Agents and Chemotherapy.

[24]  B. Dautzenberg.  Clinical trials in Mycobacterium avium therapy: lessons to take home. , 1994, Research in microbiology.

[25]  D. Papahadjopoulos,et al.  Medical applications of liposomes , 1998 .

[26]  G. Papandonatos,et al.  Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. , 1999, AIDS.

[27]  S. Siddiqi,et al.  Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis , 1981, Journal of clinical microbiology.

[28]  Horsburgh Cr.  Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. , 1991, The New England journal of medicine.

[29]  K. Florey,et al.  Analytical profiles of drug substances and excipients , 1992 .

[30]  D. Eisen,et al.  Mycobacterium avium complex causing endobronchial disease in AIDS patients after partial immune restoration. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[31]  P. Gangadharam,et al.  Differential effects of free and liposome encapsulated amikacin on the survival of Mycobacterium avium complex in mouse peritoneal macrophages. , 1990, Tubercle.

[32]  N. Düzgüneş.  Treatment of human immunodeficiency virus, Mycobacterium avium and Mycobacterium tuberculosis infections by liposome-encapsulated drugs**This chapter is dedicated to the memories of my father Professor Orhan Düzgüneş, and my father-in-law Professor John Flasher. , 1998 .

[33]  S. Piscitelli,et al.  Clarithromycin and azithromycin: new macrolide antibiotics. , 1992, Clinical pharmacy.

[34]  L. Heifets,et al.  Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium , 1994, Antimicrobial Agents and Chemotherapy.

[35]  M. Brewster,et al.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. , 1996, Journal of pharmaceutical sciences.

[36]  P. Gangadharam,et al.  Activity of free and liposome encapsulated streptomycin against Mycobacterium avium complex (MAC) inside peritoneal macrophages. , 1991, The Journal of antimicrobial chemotherapy.

[37]  R. Rohrbach,et al.  A kinetic investigation of the binding of azo dyes to cyclo-maltohexaose , 1981 .

[38]  R. Eng,et al.  Diagnosis of Mycobacterium bacteremia in patients with acquired immunodeficiency syndrome by direct examination of blood films , 1989, Journal of clinical microbiology.

[39]  G. R. Bartlett.  Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.

[40]  G. Jackson,et al.  Fungal and mycobacterial infections in patients infected with the human immunodeficiency virus. , 1989, The Journal of antimicrobial chemotherapy.

[41]  L. Heifets,et al.  Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin , 1993, Antimicrobial Agents and Chemotherapy.